US 2026/0297196 A1 · Antibody Specifically Binding to CD276, Preparation Method Therefor and Use Thereof

An antibody capable of specifically binding to CD276 protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprising:

(a) a heavy chain variable region comprising the following three complementary determining regions:
(i) VH CDR1, consisting of the following sequence:
SEQ ID NO:
3, 141 or 144, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(ii) VH CDR2, consisting of the following sequence:
SEQ ID NO:
4, 142 or 145, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(iii) VH CDR3, consisting of the following sequence:
SEQ ID NO:
5, 143 or 146, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and/or
(b) a light chain variable region comprising the following three complementary determining regions:
(iv) VL CDR1, consisting of the following sequence:
SEQ ID NO:
8, 147 or 150, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(v) VL CDR2, consisting of the following sequence:
SEQ ID NO:
9, 148 or 151, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(vi) VL CDR3, consisting of the following sequence:
SEQ ID NO:
10, 149 or 152, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
preferably, the substitution in any one of (i) to (vi) is a conservative substitution;
preferably, VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
3, VH CDR2 as shown in SEQ ID NO:
4, and VH CDR3 as shown in SEQ ID NO:
5;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
8, VL CDR2 as shown in SEQ ID NO:
9, and VL CDR3 as shown in SEQ ID NO:
10;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
141, VH CDR2 as shown in SEQ ID NO:
142, and VH CDR3 as shown in SEQ ID NO:
143;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
147, VL CDR2 as shown in SEQ ID NO:
148, and VL CDR3 as shown in SEQ ID NO:
149;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
144, VH CDR2 as shown in SEQ ID NO:
145, and VH CDR3 as shown in SEQ ID NO:
146;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
150, VL CDR2 as shown in SEQ ID NO:
151, and VL CDR3 as shown in SEQ ID NO:
152.

53 more elements

An antibody capable of specifically binding to CD276 protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprising:

(a) a heavy chain variable region comprising the following three complementary determining regions:
(i) VH CDR1, consisting of the following sequence:
SEQ ID NO:
13, 153 or 156, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(ii) VH CDR2, consisting of the following sequence:
SEQ ID NO:
14, 154 or 157, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(iii) VH CDR3, consisting of the following sequence:
SEQ ID NO:
15, 155 or 158, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and/or
(b) a light chain variable region comprising the following three complementary determining regions:
(iv) VL CDR1, consisting of the following sequence:
SEQ ID NO:
18, 159 or 162, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(v) VL CDR2, consisting of the following sequence:
SEQ ID NO:
19, 160 or 163, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(vi) VL CDR3, consisting of the following sequence:
SEQ ID NO:
20, 161 or 164, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
preferably, the substitution in any one of (i) to (vi) is a conservative substitution;
preferably, VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
13, VH CDR2 as shown in SEQ ID NO:
14, and VH CDR3 as shown in SEQ ID NO:
15;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
18, VL CDR2 as shown in SEQ ID NO:
19, and VL CDR3 as shown in SEQ ID NO:
20;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
153, VH CDR2 as shown in SEQ ID NO:
154, and VH CDR3 as shown in SEQ ID NO:
155;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
159, VL CDR2 as shown in SEQ ID NO:
160, and VL CDR3 as shown in SEQ ID NO:
161;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
156, VH CDR2 as shown in SEQ ID NO:
157, and VH CDR3 as shown in SEQ ID NO:
158;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
162, VL CDR2 as shown in SEQ ID NO:
163, and VL CDR3 as shown in SEQ ID NO:
164.

53 more elements

An antibody capable of specifically binding to CD276 protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprising:

(a) a heavy chain variable region comprising the following three complementary determining regions:
(i) VH CDR1, consisting of the following sequence:
SEQ ID NO:
23, 165 or 168, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(ii) VH CDR2, consisting of the following sequence:
SEQ ID NO:
24, 166 or 169, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(iii) VH CDR3, consisting of the following sequence:
SEQ ID NO:
25, 167 or 170, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and/or
(b) a light chain variable region comprising the following three complementary determining regions:
(iv) VL CDR1, consisting of the following sequence:
SEQ ID NO:
28, 171 or 174, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(v) VL CDR2, consisting of the following sequence:
SEQ ID NO:
29, 172 or 175, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(vi) VL CDR3, consisting of the following sequence:
SEQ ID NO:
30, 173 or 176, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
preferably, the substitution in any one of (i) to (vi) is a conservative substitution;
preferably, VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
23, VH CDR2 as shown in SEQ ID NO:
24, and VH CDR3 as shown in SEQ ID NO:
25;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
28, VL CDR2 as shown in SEQ ID NO:
29, and VL CDR3 as shown in SEQ ID NO:
30;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
165, VH CDR2 as shown in SEQ ID NO:
166, and VH CDR3 as shown in SEQ ID NO:
167;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
171, VL CDR2 as shown in SEQ ID NO:
172, and VL CDR3 as shown in SEQ ID NO:
173;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
168, VH CDR2 as shown in SEQ ID NO:
169, and VH CDR3 as shown in SEQ ID NO:
170;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
174, VL CDR2 as shown in SEQ ID NO:
175, and VL CDR3 as shown in SEQ ID NO:
176.

53 more elements

An antibody capable of specifically binding to CD276 protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprising:

(a) a heavy chain variable region comprising the following three complementary determining regions:
(i) VH CDR1, consisting of the following sequence:
SEQ ID NO:
33, 177 or 180, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(ii) VH CDR2, consisting of the following sequence:
SEQ ID NO:
34, 178 or 181, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(iii) VH CDR3, consisting of the following sequence:
SEQ ID NO:
35, 179 or 182, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and/or
(b) a light chain variable region comprising the following three complementary determining regions:
(iv) VL CDR1, consisting of the following sequence:
SEQ ID NO:
38, 183 or 186, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(v) VL CDR2, consisting of the following sequence:
SEQ ID NO:
39, 184 or 187, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(vi) VL CDR3, consisting of the following sequence:
SEQ ID NO:
40, 185 or 188, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
preferably, the substitution in any one of (i) to (vi) is a conservative substitution;
preferably, VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
33, VH CDR2 as shown in SEQ ID NO:
34, and VH CDR3 as shown in SEQ ID NO:
35;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
38, VL CDR2 as shown in SEQ ID NO:
39, and VL CDR3 as shown in SEQ ID NO:
40;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
177, VH CDR2 as shown in SEQ ID NO:
178, and VH CDR3 as shown in SEQ ID NO:
179;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
183, VL CDR2 as shown in SEQ ID NO:
184, and VL CDR3 as shown in SEQ ID NO:
185;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
180, VH CDR2 as shown in SEQ ID NO:
181, and VH CDR3 as shown in SEQ ID NO:
182;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
186, VL CDR2 as shown in SEQ ID NO:
187, and VL CDR3 as shown in SEQ ID NO:
188.

53 more elements

An antibody capable of specifically binding to CD276 protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprising:

(a) a heavy chain variable region comprising the following three complementary determining regions:
(i) VH CDR1, consisting of the following sequence:
SEQ ID NO:
43, 189 or 192, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(ii) VH CDR2, consisting of the following sequence:
SEQ ID NO:
44, 190 or 193, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(iii) VH CDR3, consisting of the following sequence:
SEQ ID NO:
45, 191 or 194, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and/or
(b) a light chain variable region comprising the following three complementary determining regions:
(iv) VL CDR1, consisting of the following sequence:
SEQ ID NO:
48, 195 or 198, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(v) VL CDR2, consisting of the following sequence:
SEQ ID NO:
49, 196 or 199, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(vi) VL CDR3, consisting of the following sequence:
SEQ ID NO:
50, 197 or 200, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
preferably, the substitution in any one of (i) to (vi) is a conservative substitution;
preferably, VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
43, VH CDR2 as shown in SEQ ID NO:
44, and VH CDR3 as shown in SEQ ID NO:
45;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
48, VL CDR2 as shown in SEQ ID NO:
49, and VL CDR3 as shown in SEQ ID NO:
50;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
189, VH CDR2 as shown in SEQ ID NO:
190, and VH CDR3 as shown in SEQ ID NO:
191;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
195, VL CDR2 as shown in SEQ ID NO:
196, and VL CDR3 as shown in SEQ ID NO:
197;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
192, VH CDR2 as shown in SEQ ID NO:
193, and VH CDR3 as shown in SEQ ID NO:
194;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
198, VL CDR2 as shown in SEQ ID NO:
199, and VL CDR3 as shown in SEQ ID NO:
200.

53 more elements

An antibody capable of specifically binding to CD276 protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprising:

(a) a heavy chain variable region comprising the following three complementary determining regions:
(i) VH CDR1, consisting of the following sequence:
SEQ ID NO:
53, 201 or 204, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(ii) VH CDR2, consisting of the following sequence:
SEQ ID NO:
54, 202 or 205, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(iii) VH CDR3, consisting of the following sequence:
SEQ ID NO:
55, 203 or 206, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and/or
(b) a light chain variable region comprising the following three complementary determining regions:
(iv) VL CDR1, consisting of the following sequence:
SEQ ID NO:
58, 207 or 210, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(v) VL CDR2, consisting of the following sequence:
SEQ ID NO:
59, 208 or 211, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(vi) VL CDR3, consisting of the following sequence:
SEQ ID NO:
60, 209 or 212, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
preferably, the substitution in any one of (i) to (vi) is a conservative substitution;
preferably, VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
53, VH CDR2 as shown in SEQ ID NO:
54, and VH CDR3 as shown in SEQ ID NO:
55;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
58, VL CDR2 as shown in SEQ ID NO:
59, and VL CDR3 as shown in SEQ ID NO:
60;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
201, VH CDR2 as shown in SEQ ID NO:
202, and VH CDR3 as shown in SEQ ID NO:
203;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
207, VL CDR2 as shown in SEQ ID NO:
208, and VL CDR3 as shown in SEQ ID NO:
209;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
204, VH CDR2 as shown in SEQ ID NO:
205, and VH CDR3 as shown in SEQ ID NO:
206;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
210, VL CDR2 as shown in SEQ ID NO:
211, and VL CDR3 as shown in SEQ ID NO:
212.

53 more elements

An antibody capable of specifically binding to CD276 protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprising:

(a) a heavy chain variable region comprising the following three complementary determining regions:
(i) VH CDR1, consisting of the following sequence:
SEQ ID NO:
63, 213 or 216, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(ii) VH CDR2, consisting of the following sequence:
SEQ ID NO:
64, 214 or 217, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(iii) VH CDR3, consisting of the following sequence:
SEQ ID NO:
65, 215 or 218, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and/or
(b) a light chain variable region comprising the following three complementary determining regions:
(iv) VL CDR1, consisting of the following sequence:
SEQ ID NO:
68, 219 or 222, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(v) VL CDR2, consisting of the following sequence:
SEQ ID NO:
69, 220 or 223, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(vi) VL CDR3, consisting of the following sequence:
SEQ ID NO:
70, 221 or 224, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
preferably, the substitution in any one of (i) to (vi) is a conservative substitution;
preferably, VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
63, VH CDR2 as shown in SEQ ID NO:
64, and VH CDR3 as shown in SEQ ID NO:
65;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
68, VL CDR2 as shown in SEQ ID NO:
69, and VL CDR3 as shown in SEQ ID NO:
70;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
213, VH CDR2 as shown in SEQ ID NO:
214, and VH CDR3 as shown in SEQ ID NO:
215;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
219, VL CDR2 as shown in SEQ ID NO:
220, and VL CDR3 as shown in SEQ ID NO:
221;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
216, VH CDR2 as shown in SEQ ID NO:
217, and VH CDR3 as shown in SEQ ID NO:
218;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
222, VL CDR2 as shown in SEQ ID NO:
223, and VL CDR3 as shown in SEQ ID NO:
224.

53 more elements

An antibody capable of specifically binding to CD276 protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprising:

(a) a heavy chain variable region comprising the following three complementary determining regions:
(i) VH CDR1, consisting of the following sequence:
SEQ ID NO:
73, 225 or 228, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(ii) VH CDR2, consisting of the following sequence:
SEQ ID NO:
74, 226 or 229, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(iii) VH CDR3, consisting of the following sequence:
SEQ ID NO:
75, 227 or 230, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and/or
(b) a light chain variable region comprising the following three complementary determining regions:
(iv) VL CDR1, consisting of the following sequence:
SEQ ID NO:
78, 231 or 234, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(v) VL CDR2, consisting of the following sequence:
SEQ ID NO:
79, 232 or 235, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(vi) VL CDR3, consisting of the following sequence:
SEQ ID NO:
80, 233 or 236, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
preferably, the substitution in any one of (i) to (vi) is a conservative substitution;
preferably, VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
73, VH CDR2 as shown in SEQ ID NO:
74, and VH CDR3 as shown in SEQ ID NO:
75;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
78, VL CDR2 as shown in SEQ ID NO:
79, and VL CDR3 as shown in SEQ ID NO:
80;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
225, VH CDR2 as shown in SEQ ID NO:
226, and VH CDR3 as shown in SEQ ID NO:
227;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
231, VL CDR2 as shown in SEQ ID NO:
232, and VL CDR3 as shown in SEQ ID NO:
233;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
228, VH CDR2 as shown in SEQ ID NO:
229, and VH CDR3 as shown in SEQ ID NO:
230;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
234, VL CDR2 as shown in SEQ ID NO:
235, and VL CDR3 as shown in SEQ ID NO:
236.

53 more elements

An antibody capable of specifically binding to CD276 protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprising:

(a) a heavy chain variable region comprising the following three complementary determining regions:
(i) VH CDR1, consisting of the following sequence:
SEQ ID NO:
83, 237 or 240, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(ii) VH CDR2, consisting of the following sequence:
SEQ ID NO:
84, 238 or 241, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(iii) VH CDR3, consisting of the following sequence:
SEQ ID NO:
85, 239 or 242, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and/or
(b) a light chain variable region comprising the following three complementary determining regions:
(iv) VL CDR1, consisting of the following sequence:
SEQ ID NO:
88, 243 or 246, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(v) VL CDR2, consisting of the following sequence:
SEQ ID NO:
89, 244 or 247, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(vi) VL CDR3, consisting of the following sequence:
SEQ ID NO:
90, 245 or 248, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
preferably, the substitution in any one of (i) to (vi) is a conservative substitution;
preferably, VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
83, VH CDR2 as shown in SEQ ID NO:
84, and VH CDR3 as shown in SEQ ID NO:
85;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
88, VL CDR2 as shown in SEQ ID NO:
89, and VL CDR3 as shown in SEQ ID NO:
90;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
237, VH CDR2 as shown in SEQ ID NO:
238, and VH CDR3 as shown in SEQ ID NO:
239;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
243, VL CDR2 as shown in SEQ ID NO:
244, and VL CDR3 as shown in SEQ ID NO:
245;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
240, VH CDR2 as shown in SEQ ID NO:
241, and VH CDR3 as shown in SEQ ID NO:
242;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
246, VL CDR2 as shown in SEQ ID NO:
247, and VL CDR3 as shown in SEQ ID NO:
248.

53 more elements

An antibody capable of specifically binding to CD276 protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprising:

(a) a heavy chain variable region comprising the following three complementary determining regions:
(i) VH CDR1, consisting of the following sequence:
SEQ ID NO:
93, 249 or 252, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(ii) VH CDR2, consisting of the following sequence:
SEQ ID NO:
94, 250 or 253, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(iii) VH CDR3, consisting of the following sequence:
SEQ ID NO:
95, 251 or 254, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and/or
(b) a light chain variable region comprising the following three complementary determining regions:
(iv) VL CDR1, consisting of the following sequence:
SEQ ID NO:
98, 255 or 258, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(v) VL CDR2, consisting of the following sequence:
SEQ ID NO:
99, 256 or 259, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(vi) VL CDR3, consisting of the following sequence:
SEQ ID NO:
100, 257 or 260, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
preferably, the substitution in any one of (i) to (vi) is a conservative substitution;
preferably, VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
93, VH CDR2 as shown in SEQ ID NO:
94, and VH CDR3 as shown in SEQ ID NO:
95;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
98, VL CDR2 as shown in SEQ ID NO:
99, and VL CDR3 as shown in SEQ ID NO:
100;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
249, VH CDR2 as shown in SEQ ID NO:
250, and VH CDR3 as shown in SEQ ID NO:
251;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
255, VL CDR2 as shown in SEQ ID NO:
256, and VL CDR3 as shown in SEQ ID NO:
257;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
252, VH CDR2 as shown in SEQ ID NO:
253, and VH CDR3 as shown in SEQ ID NO:
254;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
258, VL CDR2 as shown in SEQ ID NO:
259, and VL CDR3 as shown in SEQ ID NO:
260.

53 more elements

An antibody capable of specifically binding to CD276 protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprising:

(a) a heavy chain variable region comprising the following three complementary determining regions:
(i) VH CDR1, consisting of the following sequence:
SEQ ID NO:
103, 261 or 264, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(ii) VH CDR2, consisting of the following sequence:
SEQ ID NO:
104, 262 or 265, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(iii) VH CDR3, consisting of the following sequence:
SEQ ID NO:
105, 263 or 266, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and/or
(b) a light chain variable region comprising the following three complementary determining regions:
(iv) VL CDR1, consisting of the following sequence:
SEQ ID NO:
108, 267 or 270, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(v) VL CDR2, consisting of the following sequence:
SEQ ID NO:
109, 268 or 271, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(vi) VL CDR3, consisting of the following sequence:
SEQ ID NO:
110, 269 or 272, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
preferably, the substitution in any one of (i) to (vi) is a conservative substitution;
preferably, VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
103, VH CDR2 as shown in SEQ ID NO:
104, and VH CDR3 as shown in SEQ ID NO:
105;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
108, VL CDR2 as shown in SEQ ID NO:
109, and VL CDR3 as shown in SEQ ID NO:
110;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
261, VH CDR2 as shown in SEQ ID NO:
262, and VH CDR3 as shown in SEQ ID NO:
263;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
267, VL CDR2 as shown in SEQ ID NO:
268, and VL CDR3 as shown in SEQ ID NO:
269;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
264, VH CDR2 as shown in SEQ ID NO:
265, and VH CDR3 as shown in SEQ ID NO:
266;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
270, VL CDR2 as shown in SEQ ID NO:
271, and VL CDR3 as shown in SEQ ID NO:
272.

53 more elements

An antibody capable of specifically binding to CD276 protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprising:

(a) a heavy chain variable region comprising the following three complementary determining regions:
(i) VH CDR1, consisting of the following sequence:
SEQ ID NO:
113, 273 or 276, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(ii) VH CDR2, consisting of the following sequence:
SEQ ID NO:
114, 274 or 277, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(iii) VH CDR3, consisting of the following sequence:
SEQ ID NO:
115, 275 or 278, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and/or
(b) a light chain variable region comprising the following three complementary determining regions:
(iv) VL CDR1, consisting of the following sequence:
SEQ ID NO:
118, 279 or 282, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(v) VL CDR2, consisting of the following sequence:
SEQ ID NO:
119, 280 or 283, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(vi) VL CDR3, consisting of the following sequence:
SEQ ID NO:
120, 281 or 284, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
preferably, the substitution in any one of (i) to (vi) is a conservative substitution;
preferably, VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
113, VH CDR2 as shown in SEQ ID NO:
114, and VH CDR3 as shown in SEQ ID NO:
115;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
118, VL CDR2 as shown in SEQ ID NO:
119, and VL CDR3 as shown in SEQ ID NO:
120;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
273, VH CDR2 as shown in SEQ ID NO:
274, and VH CDR3 as shown in SEQ ID NO:
275;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
279, VL CDR2 as shown in SEQ ID NO:
280, and VL CDR3 as shown in SEQ ID NO:
281;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
276, VH CDR2 as shown in SEQ ID NO:
277, and VH CDR3 as shown in SEQ ID NO:
278;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
282, VL CDR2 as shown in SEQ ID NO:
283, and VL CDR3 as shown in SEQ ID NO:
284.

53 more elements

An antibody capable of specifically binding to CD276 protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprising:

(a) a heavy chain variable region comprising the following three complementary determining regions:
(i) VH CDR1, consisting of the following sequence:
SEQ ID NO:
123, 285 or 288, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(ii) VH CDR2, consisting of the following sequence:
SEQ ID NO:
124, 286 or 289, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(iii) VH CDR3, consisting of the following sequence:
SEQ ID NO:
125, 287 or 290, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and/or
(b) a light chain variable region comprising the following three complementary determining regions:
(iv) VL CDR1, consisting of the following sequence:
SEQ ID NO:
128, 291 or 294, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(v) VL CDR2, consisting of the following sequence:
SEQ ID NO:
129, 292 or 295, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(vi) VL CDR3, consisting of the following sequence:
SEQ ID NO:
130, 293 or 296, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
preferably, the substitution in any one of (i) to (vi) is a conservative substitution;
preferably, VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
123, VH CDR2 as shown in SEQ ID NO:
124, and VH CDR3 as shown in SEQ ID NO:
125;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
128, VL CDR2 as shown in SEQ ID NO:
129, and VL CDR3 as shown in SEQ ID NO:
130;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
285, VH CDR2 as shown in SEQ ID NO:
286, and VH CDR3 as shown in SEQ ID NO:
287;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
291, VL CDR2 as shown in SEQ ID NO:
292, and VL CDR3 as shown in SEQ ID NO:
293;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
288, VH CDR2 as shown in SEQ ID NO:
289, and VH CDR3 as shown in SEQ ID NO:
290;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
294, VL CDR2 as shown in SEQ ID NO:
295, and VL CDR3 as shown in SEQ ID NO:
296.

53 more elements

An antibody capable of specifically binding to CD276 protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprising:

(a) a heavy chain variable region comprising the following three complementary determining regions:
(i) VH CDR1, consisting of the following sequence:
SEQ ID NO:
133, 297 or 300, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(ii) VH CDR2, consisting of the following sequence:
SEQ ID NO:
134, 298 or 301, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(iii) VH CDR3, consisting of the following sequence:
SEQ ID NO:
135, 299 or 302, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and/or
(b) a light chain variable region comprising the following three complementary determining regions:
(iv) VL CDR1, consisting of the following sequence:
SEQ ID NO:
138, 303 or 306, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
(v) VL CDR2, consisting of the following sequence:
SEQ ID NO:
139, 304 or 307, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
and
(vi) VL CDR3, consisting of the following sequence:
SEQ ID NO:
140, 305 or 308, or a sequence having one or more amino acid substitutions, deletions or additions relative to any of them;
preferably, the substitution in any one of (i) to (vi) is a conservative substitution;
preferably, VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
133, VH CDR2 as shown in SEQ ID NO:
134, and VH CDR3 as shown in SEQ ID NO:
135;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
138, VL CDR2 as shown in SEQ ID NO:
139, and VL CDR3 as shown in SEQ ID NO:
140;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
297, VH CDR2 as shown in SEQ ID NO:
298, and VH CDR3 as shown in SEQ ID NO:
299;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
303, VL CDR2 as shown in SEQ ID NO:
304, and VL CDR3 as shown in SEQ ID NO:
305;
or
VH in the antibody or the antigen binding fragment thereof comprises:
VH CDR1 as shown in SEQ ID NO:
300, VH CDR2 as shown in SEQ ID NO:
301, and VH CDR3 as shown in SEQ ID NO:
302;
and VL in the antibody or the antigen binding fragment thereof comprises:
VL CDR1 as shown in SEQ ID NO:
306, VL CDR2 as shown in SEQ ID NO:
307, and VL CDR3 as shown in SEQ ID NO:
308.

53 more elements

An antibody capable of specifically binding to CD276 protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprising three CDRs comprised in the heavy chain variable region as shown in any one of SEQ ID NO:

2, 12, 22, 32, 42, 52, 62, 72, 82, 92, 102, 112, 122 or 132;
and the light chain variable region comprises three CDRs comprised in the light chain variable region as shown in any one of SEQ ID NO:
7, 17, 27, 37, 47, 57, 67, 77, 87, 97, 107, 117, 127 or 137;
preferably, the three CDRs comprised in the heavy chain variable region, and/or the three CDRs comprised in the light chain variable region, are defined by the Kabat, Chothia or IMGT numbering system.

1 more element

Antibody Specifically Binding to CD276, Preparation Method Therefor and Use Thereof

Life of this patent

Antibody Specifically Binding to CD276, Preparation Method Therefor and Use Thereof

Life of this patent

Abstract

Claims45